Fish oil and dementia prevention: what a new high-dose DHA trial found

"Should I be taking fish oil to protect my memory?" It's a common question. The honest answer has always been unsure and wrapped in many caveats. However, a new publication in the Lancet may now finally give us a clearer idea.

The PreventE4 trial

PreventE4 was a 24-month randomised, double-blind, and placebo-controlled trial. The study aimed to answer two key questions: does high-dose DHA really reach the brain, and if it does, does that change anything?

The trial included 365 healthy adults aged 55 to 80. They all had low omega-3 intake and at least one risk factor for dementia or vascular issues. Almost half had the APOE ε4 genotype — strongly linked to Alzheimer's risk and known to affect omega-3 processing. Participants took 2 g of DHA daily or a matched placebo. A subgroup had cerebrospinal fluid samples taken, allowing researchers to measure brain delivery directly rather than inferring it.

Does DHA reach the brain?

On the first question, the result was emphatic. DHA supplementation raised the CSF DHA-to-arachidonic acid ratio at six months — substantially higher than placebo — and the effect remained strong regardless of APOE ε4 status. The red cell omega-3 index roughly doubled and reached double figures. Brain penetration is not the bottleneck, even in people who carry the higher-risk genotype and start with low intake.

Does it change anything?

On the second question, nothing moved. Over 24 months, there was no measurable difference in hippocampal volume, cortical thickness, or cognitive scores between groups.¹ These outcomes were exploratory and reported without p-values or adjustments for multiple tests. The population was relatively young, well educated, and cognitively intact, with minimal baseline atrophy — so there was limited opportunity for an intervention to show benefit. Even so, the direction of travel is consistent with the broader evidence.

The VITAL trial (first published four years ago) also found no cognitive benefit from omega-3 over two to three years in more than 4,000 older adults,² and a recent systematic review found positive cognitive effects in only a fifth of trials in people without dementia.³

The clinical message

The clinical message is not that omega-3 is irrelevant, but that getting it into the brain is the easy part. Supplementation alone — even at high doses and in a genetically enriched group — did not protect cognition or brain structure. The authors suggest focusing on mechanisms rather than higher doses, and recommend multimodal strategies that address vascular risk, inactivity, and metabolic health alongside any nutrient.

References

1. Yassine HN, Ghasem Pour S, Juarez M, et al. CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial. eBioMedicine 2026 (in press). doi.org/10.1016/j.ebiom.2026.106316
2. Kang JH, Vyas CM, Okereke OI, et al. Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial. Alzheimers Dement 2022;8(1):e12288
3. Yassine HN, Carrasco AS, Badie DS. Designing newer omega-3 supplementation trials for cognitive outcomes: a systematic review guided analysis. J Alzheimers Dis 2024;101(s1):S455–S466